Adial Financial Statements From 2010 to 2024

ADILWDelisted Stock  USD 0.01  0  52.50%   
Adial Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Adial Pharmaceuticals WT investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Adial Pharmaceuticals financial statements helps investors assess Adial Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Adial Pharmaceuticals' valuation are summarized below:
Adial Pharmaceuticals WT does not presently have any fundamental signals for analysis.
Check Adial Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adial Pharmaceuticals' main balance sheet or income statement drivers, such as , as well as many indicators such as . Adial financial statements analysis is a perfect complement when working with Adial Pharmaceuticals Valuation or Volatility modules.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Adial Pharmaceuticals WT Company Cash Flow From Operations Analysis

Adial Pharmaceuticals' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

Operating Cash Flow

 = 

EBITDA

-

Taxes

More About Cash Flow From Operations | All Equity Analysis

Current Adial Pharmaceuticals Cash Flow From Operations

    
  (11.19 M)  
Most of Adial Pharmaceuticals' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Adial Pharmaceuticals WT is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
Competition

In accordance with the recently published financial statements, Adial Pharmaceuticals WT has (11.19 Million) in Cash Flow From Operations. This is much lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The cash flow from operations for all United States stocks is notably higher than that of the company.

Adial Pharmaceuticals Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Adial Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Adial Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Adial Pharmaceuticals competition to find correlations between indicators driving Adial Pharmaceuticals's intrinsic value. More Info.
Adial Pharmaceuticals WT is rated second in number of shares shorted category among its peers. It is rated fifth in ebitda category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value Adial Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.

About Adial Pharmaceuticals Financial Statements

Adial Pharmaceuticals investors use historical fundamental indicators, such as Adial Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Adial Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.

Other Consideration for investing in Adial Stock

If you are still planning to invest in Adial Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Adial Pharmaceuticals' history and understand the potential risks before investing.
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Stocks Directory
Find actively traded stocks across global markets
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.